The odds were daunting: AbbVie Inc. was facing its third bellwether trial over its prescription testosterone supplement Androgel, and it was up to Kirkland & Ellis partner James Hurst to turn the tide.

The first two trials didn’t go well. The company was hit with verdicts of $150 million and $140 million last year after Chicago juries found it fraudulently misrepresented Androgel’s risks. (The $150 million award was overturned by the judge.)

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]